bioRxivCancer Biology
Longitudinal analysis of diffuse glioma reveals cell state dynamics at recurrence associated with changes in genetics and the microenvironment
F. S. Varn, K. C. Johnson, T. E. Wade, T. M. Malta, T. S. Sabedot, F. P. Barthel, H. Kim, N. Ahmed, I. Datta, J. S. Barnholtz-Sloan, S. Bakas, F. D'Angelo, H. K. Gan, L. Garofano, J. T. Huse, M. Khasraw, E. Kocakavuk, S. Migliozzi, D. R. Ormond, S. H. Paek, E. G. Van Meir, A. M. E. Walenkamp, C. Watts, M. Weller, T. Weiss, , The GLASS Consortium
Abstract
To interrogate the factors driving therapy resistance in diffuse glioma, we collected and analyzed RNA and/or DNA sequencing data from temporally separated tumor pairs of 292 adult patients with IDH-wild-type or IDH-mutant glioma. Tumors recurred in distinct manners that were dependent on IDH mutation status and attributable to changes in histological feature composition, somatic alterations, and microenvironment interactions. Hypermutation and acquired CDKN2A deletions associated with an increase in proliferating stem-like malignant cells at recurrence in both glioma subtypes, reflecting active tumor growth. IDH-wild-type tumors were more invasive at recurrence, and their malignant cells exhibited increased expression of neuronal signaling programs that reflected a possible role for neuronal interactions in promoting glioma progression. Mesenchymal transition was associated with the presence of a specific myeloid cell state defined by unique ligand-receptor interactions with malignant cells. Collectively, our results uncover recurrence-associated changes that could be targetable to shape disease progression following initial diagnosis.
- organism: human
- assay: bulk RNA-seq
- assay: whole-exome sequencing
- research focus: cell type annotation
- research focus: differential expression
- research focus: cell-cell communication
- research focus: clustering
- approach: statistical model
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The epigenetic evolution of gliomas is determined by their IDH1 mutation status and treatment regimen
Tathiane Maistro Malta, Thaís S. Sabedot, … Peter S. LaViolette·Cancer ResearchPeer-reviewed·Dec 20, 2023
- Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas
Tamrin Chowdhury, C. Mircea S. Tesileanu, … Roel G.W. Verhaak·bioRxiv·Jul 11, 2025
- Tumor evolution of glioma intrinsic gene expression subtype associates with immunological changes in the microenvironment
Qianghu Wang, Xin Hu, … Roel G.W. Verhaak·Cancer CellPeer-reviewed·Jul 1, 2017
- A Network-Based Discovery of Prognostic Markers in Recurrent IDH wild-type Gliomas
Yang Liu, Jason T. Huse, Kasthuri Kannan·Frontiers in GeneticsPeer-reviewed·Nov 20, 2025
- Adult-type diffuse gliomas share recurring cell states driven by a common astrocyte-like glioma stem cell population
Walter Muskovic, Ashraf Zaman, … Joseph E. Powell·bioRxiv·Jun 13, 2024
- Glioma Through the Looking GLASS: the Glioma Longitudinal Analysis consortium, molecular evolution of diffuse gliomas
The Glioma Longitudinal Analysis Consortium, R. Verhaak·bioRxiv·Oct 2, 2017